首页 > 最新文献

Journal of Pharmaceutical Health Care and Sciences最新文献

英文 中文
Preliminary clinical evaluation of cefmetazole dosing regimens in Japanese patients with urinary tract infections. 日本尿路感染患者头孢美唑给药方案的初步临床评价。
IF 1.2 Q4 PHARMACOLOGY & PHARMACY Pub Date : 2025-12-27 DOI: 10.1186/s40780-025-00535-1
Yuna Sadaka, Kokoro Nakajima, Yuki Sasaki, Mao Tsurugaya, Yasuhisa Oida, Midori Soda, Tomoyuki Hirashita, Kotoe Inoue, Yoshito Takahashi, Tsuyoshi Yokoi, Kiyoyuki Kitaichi
{"title":"Preliminary clinical evaluation of cefmetazole dosing regimens in Japanese patients with urinary tract infections.","authors":"Yuna Sadaka, Kokoro Nakajima, Yuki Sasaki, Mao Tsurugaya, Yasuhisa Oida, Midori Soda, Tomoyuki Hirashita, Kotoe Inoue, Yoshito Takahashi, Tsuyoshi Yokoi, Kiyoyuki Kitaichi","doi":"10.1186/s40780-025-00535-1","DOIUrl":"10.1186/s40780-025-00535-1","url":null,"abstract":"","PeriodicalId":16730,"journal":{"name":"Journal of Pharmaceutical Health Care and Sciences","volume":" ","pages":"12"},"PeriodicalIF":1.2,"publicationDate":"2025-12-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12853748/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145846840","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Impact of a tailored, department-specific antimicrobial stewardship team intervention based on AWaRe guidelines: a single-center, cohort, interrupted-time series study. 基于AWaRe指南的针对特定科室的抗菌素管理团队干预的影响:一项单中心、队列、中断时间序列研究
IF 1.2 Q4 PHARMACOLOGY & PHARMACY Pub Date : 2025-12-25 DOI: 10.1186/s40780-025-00525-3
Yusuke Yagi, Yu Arakawa, Yukihiro Hamada, Yuka Yamagishi

Background: The global crisis of antimicrobial resistance (AMR) necessitates robust antimicrobial stewardship. The World Health Organization's (WHO) Access, Watch, Reserve (AWaRe) classification is a key tool for guiding antibiotic prescribing to combat AMR. The WHO's global target was to have at least 60% of antibiotic consumption fall into the Access category by 2023. This study evaluated the effectiveness of localized interventions toward this goal.

Methods: This retrospective, longitudinal study analyzed oral outpatient antibiotic prescriptions at Kochi Medical School Hospital from April 2022 to June 2025. Data included defined daily doses (DDDs), days of therapy (DOTs), and AWaRe classifications. Based on a preceding analysis, the antimicrobial stewardship team (AST) implemented targeted, department-specific educational interventions starting in April 2024. The impact was evaluated using seasonally adjusted time-series analysis and regression models. The study also included a survey of Escherichia coli susceptibility to levofloxacin, ciprofloxacin, and sulfamethoxazole/trimethoprim from outpatient urinary isolates.

Results: The AST intervention led to a statistically significant increase in the usage proportion and DDDs of Access antibiotics (+ 2.92%, p = 0.005 and + 376.5 DDDs, p = 0.001, respectively), with a corresponding decrease in Watch antibiotics (-3.00%, p = 0.003). However, DOTs did not significantly change, indicating the intervention primarily impacted drug choice, not treatment duration. Top prescribed agents were clarithromycin (24.2%), sulfamethoxazole/trimethoprim (20.7%), and rifaximin (10.7%). E. coli susceptibility to levofloxacin and ciprofloxacin was low (< 80% overall), particularly in extended-spectrum β-lactamase (ESBL)-producing strains (~ 10%). Sulfamethoxazole/trimethoprim susceptibility remained high overall (≥ 80%) but was low (< 80%) for ESBL-producing strains.

Conclusions: AST interventions successfully shifted outpatient prescribing from Watch to Access antibiotics, demonstrating that targeted interventions can modify prescribing behavior. However, challenges remain, such as addressing treatment duration and achieving broader goals. The observed resistance patterns highlight the critical need for prescribers to consult local antibiograms. Future strategies require a more comprehensive approach, including real-time alerts and improved diagnostics, to further optimize antibiotic use and combat AMR.

背景:抗菌素耐药性(AMR)的全球危机需要强有力的抗菌素管理。世界卫生组织(世卫组织)的获取、观察和储备(AWaRe)分类是指导抗生素处方以对抗抗生素耐药性的关键工具。世卫组织的全球目标是到2023年使至少60%的抗生素消费属于可获得类别。本研究评估了实现这一目标的局部干预措施的有效性。方法:回顾性、纵向分析高知医学院医院2022年4月至2025年6月门诊口服抗生素处方。数据包括定义的每日剂量(DDDs)、治疗天数(DOTs)和AWaRe分类。根据之前的分析,抗菌素管理团队(AST)从2024年4月开始实施有针对性的部门特定教育干预措施。使用季节调整的时间序列分析和回归模型来评估影响。该研究还包括调查门诊泌尿分离株大肠杆菌对左氧氟沙星、环丙沙星和磺胺甲恶唑/甲氧苄啶的敏感性。结果:AST干预导致Access类抗生素使用比例和DDDs分别增加(+ 2.92%,p = 0.005和+ 376.5 DDDs, p = 0.001), Watch类抗生素使用比例和DDDs相应下降(-3.00%,p = 0.003)。然而,DOTs没有显著变化,表明干预主要影响药物选择,而不是治疗时间。排在前列的处方药物为克拉霉素(24.2%)、磺胺甲恶唑/甲氧苄啶(20.7%)和利福昔明(10.7%)。大肠杆菌对左氧氟沙星和环丙沙星的敏感性较低(结论:AST干预成功地将门诊处方从Watch转向了Access,表明有针对性的干预可以改变处方行为。然而,挑战仍然存在,例如解决治疗时间和实现更广泛的目标。观察到的耐药模式突出了开处方者查阅当地抗生素图的迫切需要。未来的战略需要更全面的方法,包括实时警报和改进诊断,以进一步优化抗生素的使用和抗击抗生素耐药性。
{"title":"Impact of a tailored, department-specific antimicrobial stewardship team intervention based on AWaRe guidelines: a single-center, cohort, interrupted-time series study.","authors":"Yusuke Yagi, Yu Arakawa, Yukihiro Hamada, Yuka Yamagishi","doi":"10.1186/s40780-025-00525-3","DOIUrl":"10.1186/s40780-025-00525-3","url":null,"abstract":"<p><strong>Background: </strong>The global crisis of antimicrobial resistance (AMR) necessitates robust antimicrobial stewardship. The World Health Organization's (WHO) Access, Watch, Reserve (AWaRe) classification is a key tool for guiding antibiotic prescribing to combat AMR. The WHO's global target was to have at least 60% of antibiotic consumption fall into the Access category by 2023. This study evaluated the effectiveness of localized interventions toward this goal.</p><p><strong>Methods: </strong>This retrospective, longitudinal study analyzed oral outpatient antibiotic prescriptions at Kochi Medical School Hospital from April 2022 to June 2025. Data included defined daily doses (DDDs), days of therapy (DOTs), and AWaRe classifications. Based on a preceding analysis, the antimicrobial stewardship team (AST) implemented targeted, department-specific educational interventions starting in April 2024. The impact was evaluated using seasonally adjusted time-series analysis and regression models. The study also included a survey of Escherichia coli susceptibility to levofloxacin, ciprofloxacin, and sulfamethoxazole/trimethoprim from outpatient urinary isolates.</p><p><strong>Results: </strong>The AST intervention led to a statistically significant increase in the usage proportion and DDDs of Access antibiotics (+ 2.92%, p = 0.005 and + 376.5 DDDs, p = 0.001, respectively), with a corresponding decrease in Watch antibiotics (-3.00%, p = 0.003). However, DOTs did not significantly change, indicating the intervention primarily impacted drug choice, not treatment duration. Top prescribed agents were clarithromycin (24.2%), sulfamethoxazole/trimethoprim (20.7%), and rifaximin (10.7%). E. coli susceptibility to levofloxacin and ciprofloxacin was low (< 80% overall), particularly in extended-spectrum β-lactamase (ESBL)-producing strains (~ 10%). Sulfamethoxazole/trimethoprim susceptibility remained high overall (≥ 80%) but was low (< 80%) for ESBL-producing strains.</p><p><strong>Conclusions: </strong>AST interventions successfully shifted outpatient prescribing from Watch to Access antibiotics, demonstrating that targeted interventions can modify prescribing behavior. However, challenges remain, such as addressing treatment duration and achieving broader goals. The observed resistance patterns highlight the critical need for prescribers to consult local antibiograms. Future strategies require a more comprehensive approach, including real-time alerts and improved diagnostics, to further optimize antibiotic use and combat AMR.</p>","PeriodicalId":16730,"journal":{"name":"Journal of Pharmaceutical Health Care and Sciences","volume":" ","pages":"11"},"PeriodicalIF":1.2,"publicationDate":"2025-12-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12849487/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145834125","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Temporal trends in the prescription of traditional Japanese herbal (Kampo) medicines to pregnant women: analysis of an administrative hospital database in Japan. 孕妇使用传统日本草药(汉方)处方的时间趋势:对日本一家行政医院数据库的分析。
IF 1.2 Q4 PHARMACOLOGY & PHARMACY Pub Date : 2025-12-24 DOI: 10.1186/s40780-025-00515-5
Daisuke Kikuchi, Taku Obara, Shiro Hatakeyama, Risa Josaka, Misaki Tokunaga, Kouji Okada, Yuriko Murai

Background: Japanese traditional (Kampo) medicines are commonly prescribed in clinical practice, with increasing evidence supporting their use during pregnancy. The efficacy and safety of Kampo medicines during pregnancy have increasingly been studied; however, evidence in support of these medicines is inadequate. Thus, we conducted a temporal trend analysis of Kampo medicine prescriptions to determine the Kampo medicines for which further safety evidence is required.

Methods: Administrative data from pregnant Japanese women who visited acute-care diagnosis procedure combination hospitals between January 1, 2014, and December 31, 2023, were used in this study. Therapeutic categories related to the Kyoto Encyclopedia of Genes and Genomes D numbers 5100 and 5200 were defined as target Kampo medicines. Annual prescription trends were calculated as proportions. Temporal trends in the proportion of prescriptions for each Kampo medicine were assessed using the Cochran-Armitage trend test. Statistical significance was set at p < 0.05.

Results: Between 2014 and 2023, the proportion of Kampo medicine prescriptions increased significantly from 12.0% to 13.6% (p < 0.001). As of 2023, tokishakuyakusan (2.9%) was the most prescribed medication, followed by kakkonto (2.4%) and daikenchuto (2.0%). From 2014 to 2023, the proportions of tokishakuyakusan (3.3% to 2.9%) and kakkonto (2.4% to 2.4%) prescriptions showed no significant temporal changes (p = 0.07 and 0.36, respectively). In contrast, the proportion of daikenchuto prescriptions increased significantly from 0.8% to 2.0% (p < 0.001).

Conclusion: The primary prescribed Kampo medicines were those with established safety evidence for use in pregnant women. The proportion of Kampo medicine prescriptions for pregnant women in Japan has increased over time, with tokishakuyakusan being the most prescribed during the study period.

背景:日本传统(汉布)药物在临床实践中常用,越来越多的证据支持其在怀孕期间使用。对怀孕期间使用汉布药的有效性和安全性的研究越来越多;然而,支持这些药物的证据不足。因此,我们对汉布药处方进行了时间趋势分析,以确定需要进一步安全性证据的汉布药。方法:本研究采用2014年1月1日至2023年12月31日期间在急症诊断程序联合医院就诊的日本孕妇的管理资料。与京都基因和基因组百科全书D号5100和5200相关的治疗类别被定义为目标汉布药物。年度处方趋势以比例计算。使用Cochran-Armitage趋势检验评估每种柬埔寨药处方比例的时间趋势。结果:2014 - 2023年,汉布药处方占比由12.0%显著上升至13.6% (p)。结论:主要处方的汉布药为已确立安全性证据的孕妇用药。随着时间的推移,日本孕妇处方的汉布药比例有所增加,在研究期间,tokishakuyakusan是处方最多的药物。
{"title":"Temporal trends in the prescription of traditional Japanese herbal (Kampo) medicines to pregnant women: analysis of an administrative hospital database in Japan.","authors":"Daisuke Kikuchi, Taku Obara, Shiro Hatakeyama, Risa Josaka, Misaki Tokunaga, Kouji Okada, Yuriko Murai","doi":"10.1186/s40780-025-00515-5","DOIUrl":"10.1186/s40780-025-00515-5","url":null,"abstract":"<p><strong>Background: </strong>Japanese traditional (Kampo) medicines are commonly prescribed in clinical practice, with increasing evidence supporting their use during pregnancy. The efficacy and safety of Kampo medicines during pregnancy have increasingly been studied; however, evidence in support of these medicines is inadequate. Thus, we conducted a temporal trend analysis of Kampo medicine prescriptions to determine the Kampo medicines for which further safety evidence is required.</p><p><strong>Methods: </strong>Administrative data from pregnant Japanese women who visited acute-care diagnosis procedure combination hospitals between January 1, 2014, and December 31, 2023, were used in this study. Therapeutic categories related to the Kyoto Encyclopedia of Genes and Genomes D numbers 5100 and 5200 were defined as target Kampo medicines. Annual prescription trends were calculated as proportions. Temporal trends in the proportion of prescriptions for each Kampo medicine were assessed using the Cochran-Armitage trend test. Statistical significance was set at p < 0.05.</p><p><strong>Results: </strong>Between 2014 and 2023, the proportion of Kampo medicine prescriptions increased significantly from 12.0% to 13.6% (p < 0.001). As of 2023, tokishakuyakusan (2.9%) was the most prescribed medication, followed by kakkonto (2.4%) and daikenchuto (2.0%). From 2014 to 2023, the proportions of tokishakuyakusan (3.3% to 2.9%) and kakkonto (2.4% to 2.4%) prescriptions showed no significant temporal changes (p = 0.07 and 0.36, respectively). In contrast, the proportion of daikenchuto prescriptions increased significantly from 0.8% to 2.0% (p < 0.001).</p><p><strong>Conclusion: </strong>The primary prescribed Kampo medicines were those with established safety evidence for use in pregnant women. The proportion of Kampo medicine prescriptions for pregnant women in Japan has increased over time, with tokishakuyakusan being the most prescribed during the study period.</p>","PeriodicalId":16730,"journal":{"name":"Journal of Pharmaceutical Health Care and Sciences","volume":"11 1","pages":"112"},"PeriodicalIF":1.2,"publicationDate":"2025-12-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12729618/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145827894","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Efficacy of protocol-based pharmacotherapy management in switching of antibiotic administration routes and dose adjustment based on renal function: a before-after study. 基于方案的药物治疗管理在基于肾功能的抗生素给药途径切换和剂量调整中的疗效:一项前后研究。
IF 1.2 Q4 PHARMACOLOGY & PHARMACY Pub Date : 2025-12-24 DOI: 10.1186/s40780-025-00512-8
Yuki Sato, Yudai Takatani, Shunsaku Nakagawa, Yoshiki Katada, Yasuhiro Tsuchido, Mitsuhiro Sugimoto, Masanori Kimata, Mamiko Saigo, Masahiro Tsuda, Shigeru Ohtsuru, Tomohiro Terada
{"title":"Efficacy of protocol-based pharmacotherapy management in switching of antibiotic administration routes and dose adjustment based on renal function: a before-after study.","authors":"Yuki Sato, Yudai Takatani, Shunsaku Nakagawa, Yoshiki Katada, Yasuhiro Tsuchido, Mitsuhiro Sugimoto, Masanori Kimata, Mamiko Saigo, Masahiro Tsuda, Shigeru Ohtsuru, Tomohiro Terada","doi":"10.1186/s40780-025-00512-8","DOIUrl":"10.1186/s40780-025-00512-8","url":null,"abstract":"","PeriodicalId":16730,"journal":{"name":"Journal of Pharmaceutical Health Care and Sciences","volume":"11 1","pages":"113"},"PeriodicalIF":1.2,"publicationDate":"2025-12-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12729801/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145827960","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Successful re-administration after nano-liposomal irinotecan-induced severe hypersensitivity reaction: a case report. 伊立替康纳米脂质体诱导严重超敏反应后再给药成功1例。
IF 1.2 Q4 PHARMACOLOGY & PHARMACY Pub Date : 2025-12-22 DOI: 10.1186/s40780-025-00514-6
Ryota Kanno, Yoshitaka Saito, Yoh Takekuma, Kazuaki Harada, Yoshito Komatsu, Mitsuru Sugawara

Background: Nano-liposomal irinotecan (nal-IRI) combined with 5-fluorouracil (5-FU) and levofolinate has been reported to extend the survival of patients with pancreatic cancer and represents an effective second-line treatment. Nal-IRI encapsulates IRI in liposomes modified with polyethylene glycol (PEGylation), which can lead to infusion reactions. Hypersensitivity reactions (HSR) to chemotherapeutic agents include both allergic and infusion reactions, which are difficult to distinguish. Severe HSR can be fatal; however, discontinuation of the suspected drug directly affects the treatment strategy. We report a case of severe HSR during the first nal-IRI administration, in which treatment was successfully continued with supportive management.

Case presentation: A woman in her early 80s with metastatic pancreatic cancer received nal-IRI + 5-FU + levofolinate as second-line treatment. Five minutes after the initiation of the first nal-IRI infusion, the patient developed a tightening sensation in the head, respiratory distress, convulsions, and loss of consciousness, with percutaneous oxygen saturation dropping to the 80% range. The nal-IRI infusion was immediately discontinued, and emergency management was initiated with intravenous infusion of hydrocortisone, famotidine, d-chlorpheniramine maleate, and oxygen administration, resulting in symptom improvement. Given the limited treatment options for metastatic pancreatic cancer and the patient's strong desire to continue therapy, we decided to re-administer the regimen with intensified management, increasing dexamethasone to 19.8 mg and adding famotidine 20 mg and d-chlorpheniramine maleate 5 mg. Furthermore, we adopted a three-step dose-escalation method. The infusion was started at one-third of the standard rate, increased to two-thirds after 30 min, and finally adjusted to the full rate after another 30 min, after confirming the absence of HSR symptoms. Consequently, the patient did not exhibit any signs of HSR, and the same administration method was continued for 11 cycles until disease progression.

Conclusions: The novelty of this report lies in presenting, for the first time, the detailed course and process by which treatment was successfully continued in a patient experiencing severe HSR upon initial nal-IRI administration, through enhanced supportive care tailored to the characteristics of the drug and stepwise dose adjustment.

背景:纳米伊立替康脂质体(nal-IRI)联合5-氟尿嘧啶(5-FU)和左旋叶酸盐已被报道可延长胰腺癌患者的生存期,是一种有效的二线治疗方法。Nal-IRI将IRI封装在聚乙二醇修饰的脂质体中,这可能导致输液反应。化疗药物的超敏反应(HSR)包括过敏反应和输液反应,两者难以区分。严重的高铁可能致命;然而,停药直接影响治疗策略。我们报告一例严重HSR在第一次nal-IRI管理期间,治疗成功地继续支持管理。病例介绍:一名80岁出头的女性转移性胰腺癌接受nal-IRI + 5-FU +左旋叶酸盐作为二线治疗。首次nal-IRI输注5分钟后,患者出现头部收紧感、呼吸窘迫、抽搐和意识丧失,经皮氧饱和度降至80%范围。立即停止nal-IRI输注,并开始紧急处理,静脉输注氢化可的松、法莫替丁、马来酸d-氯苯那敏和给氧,导致症状改善。考虑到转移性胰腺癌的治疗选择有限以及患者继续治疗的强烈愿望,我们决定在加强管理的情况下重新实施该方案,将地塞米松增加到19.8 mg,法莫替丁增加20 mg,马来酸d-氯苯那敏5 mg。此外,我们采用了三步剂量递增法。以标准速率的三分之一开始输注,30分钟后增加到三分之二,再过30分钟,在确认HSR症状消失后,最终调整到全速。因此,患者没有表现出任何HSR的迹象,并且相同的给药方法持续了11个周期,直到疾病进展。结论:该报告的新颖之处在于,首次提出了在首次给药后,通过针对药物特性和逐步剂量调整的增强支持治疗,成功地继续治疗严重HSR患者的详细过程和过程。
{"title":"Successful re-administration after nano-liposomal irinotecan-induced severe hypersensitivity reaction: a case report.","authors":"Ryota Kanno, Yoshitaka Saito, Yoh Takekuma, Kazuaki Harada, Yoshito Komatsu, Mitsuru Sugawara","doi":"10.1186/s40780-025-00514-6","DOIUrl":"10.1186/s40780-025-00514-6","url":null,"abstract":"<p><strong>Background: </strong>Nano-liposomal irinotecan (nal-IRI) combined with 5-fluorouracil (5-FU) and levofolinate has been reported to extend the survival of patients with pancreatic cancer and represents an effective second-line treatment. Nal-IRI encapsulates IRI in liposomes modified with polyethylene glycol (PEGylation), which can lead to infusion reactions. Hypersensitivity reactions (HSR) to chemotherapeutic agents include both allergic and infusion reactions, which are difficult to distinguish. Severe HSR can be fatal; however, discontinuation of the suspected drug directly affects the treatment strategy. We report a case of severe HSR during the first nal-IRI administration, in which treatment was successfully continued with supportive management.</p><p><strong>Case presentation: </strong>A woman in her early 80s with metastatic pancreatic cancer received nal-IRI + 5-FU + levofolinate as second-line treatment. Five minutes after the initiation of the first nal-IRI infusion, the patient developed a tightening sensation in the head, respiratory distress, convulsions, and loss of consciousness, with percutaneous oxygen saturation dropping to the 80% range. The nal-IRI infusion was immediately discontinued, and emergency management was initiated with intravenous infusion of hydrocortisone, famotidine, d-chlorpheniramine maleate, and oxygen administration, resulting in symptom improvement. Given the limited treatment options for metastatic pancreatic cancer and the patient's strong desire to continue therapy, we decided to re-administer the regimen with intensified management, increasing dexamethasone to 19.8 mg and adding famotidine 20 mg and d-chlorpheniramine maleate 5 mg. Furthermore, we adopted a three-step dose-escalation method. The infusion was started at one-third of the standard rate, increased to two-thirds after 30 min, and finally adjusted to the full rate after another 30 min, after confirming the absence of HSR symptoms. Consequently, the patient did not exhibit any signs of HSR, and the same administration method was continued for 11 cycles until disease progression.</p><p><strong>Conclusions: </strong>The novelty of this report lies in presenting, for the first time, the detailed course and process by which treatment was successfully continued in a patient experiencing severe HSR upon initial nal-IRI administration, through enhanced supportive care tailored to the characteristics of the drug and stepwise dose adjustment.</p>","PeriodicalId":16730,"journal":{"name":"Journal of Pharmaceutical Health Care and Sciences","volume":"11 1","pages":"110"},"PeriodicalIF":1.2,"publicationDate":"2025-12-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12723823/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145809582","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Association between dispensing regulations for extended-release methylphenidate and prescription trends in Japan: an exploratory descriptive study. 日本缓释哌甲酯配药法规与处方趋势之间的关联:一项探索性描述性研究。
IF 1.2 Q4 PHARMACOLOGY & PHARMACY Pub Date : 2025-12-22 DOI: 10.1186/s40780-025-00531-5
Kazumasa Kotake, Toshiki Nakamura, Yuki Nakano, Naoya Kitamura
{"title":"Association between dispensing regulations for extended-release methylphenidate and prescription trends in Japan: an exploratory descriptive study.","authors":"Kazumasa Kotake, Toshiki Nakamura, Yuki Nakano, Naoya Kitamura","doi":"10.1186/s40780-025-00531-5","DOIUrl":"10.1186/s40780-025-00531-5","url":null,"abstract":"","PeriodicalId":16730,"journal":{"name":"Journal of Pharmaceutical Health Care and Sciences","volume":" ","pages":"111"},"PeriodicalIF":1.2,"publicationDate":"2025-12-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12729221/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145809847","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Postoperative opioid-free analgesia with acetaminophen and its impact on pain and postoperative nausea and vomiting following arthroscopic rotator cuff repair: a single-center retrospective study. 对乙酰氨基酚术后无阿片类镇痛及其对关节镜下肩袖修复术后疼痛和术后恶心呕吐的影响:一项单中心回顾性研究
IF 1.2 Q4 PHARMACOLOGY & PHARMACY Pub Date : 2025-12-22 DOI: 10.1186/s40780-025-00530-6
Misa Okizuka, Ryo Inose, Shiho Maruoka, Mikiko Takeuchi, Subaru Hirotsu, Miki Nakamura, Yuichi Muraki
{"title":"Postoperative opioid-free analgesia with acetaminophen and its impact on pain and postoperative nausea and vomiting following arthroscopic rotator cuff repair: a single-center retrospective study.","authors":"Misa Okizuka, Ryo Inose, Shiho Maruoka, Mikiko Takeuchi, Subaru Hirotsu, Miki Nakamura, Yuichi Muraki","doi":"10.1186/s40780-025-00530-6","DOIUrl":"10.1186/s40780-025-00530-6","url":null,"abstract":"","PeriodicalId":16730,"journal":{"name":"Journal of Pharmaceutical Health Care and Sciences","volume":" ","pages":"115"},"PeriodicalIF":1.2,"publicationDate":"2025-12-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12751185/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145809869","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Impact of a local formulary on prescribing patterns and pharmaceutical expenditure: an observational study in Japan. 地方处方对处方模式和医药支出的影响:日本的一项观察性研究。
IF 1.2 Q4 PHARMACOLOGY & PHARMACY Pub Date : 2025-12-22 DOI: 10.1186/s40780-025-00526-2
Hirofumi Koike, Maho Taguchi, Akihiro Koide, Hiroaki Yamada

Background: The implementation of local formularies in Japan began in November 2018 in the Sakata area of Yamagata Prefecture. A local formulary is a regional list of recommended pharmaceuticals selected based on comprehensive criteria, including efficacy, safety, and economic considerations. However, the economic impact of these formulations has not yet been clearly demonstrated. This retrospective observational study aimed to verify their effectiveness by analyzing real-world data.

Methods: Prescription and outpatient data from the National Database were extracted for October 2018, 2019, and 2020, covering both the Sakata area and the rest of Yamagata Prefecture. The number of prescriptions and cost per prescription were calculated for four therapeutic classes: proton pump inhibitors/potassium-competitive acid blockers, angiotensin receptor blockers, α-glucosidase inhibitors, and statins.

Results: In 2020, the formulary adherence rate in Sakata exceeded that in the rest of Yamagata Prefecture across all therapeutic classes. Although the cost per prescription annually decreased in Sakata, some therapeutic classes showed increased costs in the remainder of the prefecture from 2019 to 2020. In contrast, formulary adherence to outpatient medical prescriptions was lower in Sakata, and no clear impact of the local formulary was observed. Applying the rate of cost reduction observed in Sakata to the rest of the prefecture, the estimated monthly savings reached approximately 35 million JPY after 1 year and 15 million JPY after 2 years. Furthermore, although no prior measures existed to control the use of originator drugs without generics, Sakata showed a trend of reduced usage compared with the rest of the prefecture, suggesting the influence of the local formulary.

Conclusions: Local formularies can contribute to the sustainability of Japan's healthcare financing systems.

背景:日本于2018年11月开始在山形县坂田地区实施地方配方。地方处方集是根据综合标准(包括疗效、安全性和经济性考虑因素)选择的推荐药物的区域清单。然而,这些方案的经济影响尚未得到明确证明。本回顾性观察研究旨在通过分析真实世界的数据来验证其有效性。方法:从国家数据库中提取2018年10月、2019年10月和2020年10月的处方和门诊数据,涵盖坂田地区和山形县其他地区。计算了质子泵抑制剂/钾竞争性酸阻滞剂、血管紧张素受体阻滞剂、α-葡萄糖苷酶抑制剂和他汀类药物四种治疗类别的处方数量和每张处方费用。结果:2020年,在所有治疗类别中,坂田的处方依从率超过了山形县其他地区。尽管坂田地区每年的处方费用有所下降,但从2019年到2020年,该地区其他地区的一些治疗类费用有所增加。相比之下,Sakata的处方依从性较低,没有观察到当地处方的明显影响。将坂田县的成本降低率应用到县内其他地区,预计一年后每月节省约3500万日元,两年后每月节省1500万日元。此外,虽然没有事先采取措施来控制非仿制药的原药使用,但Sakata与县内其他地区相比,其使用量有减少的趋势,这表明当地处方的影响。结论:地方处方可以促进日本医疗保健融资系统的可持续性。
{"title":"Impact of a local formulary on prescribing patterns and pharmaceutical expenditure: an observational study in Japan.","authors":"Hirofumi Koike, Maho Taguchi, Akihiro Koide, Hiroaki Yamada","doi":"10.1186/s40780-025-00526-2","DOIUrl":"10.1186/s40780-025-00526-2","url":null,"abstract":"<p><strong>Background: </strong>The implementation of local formularies in Japan began in November 2018 in the Sakata area of Yamagata Prefecture. A local formulary is a regional list of recommended pharmaceuticals selected based on comprehensive criteria, including efficacy, safety, and economic considerations. However, the economic impact of these formulations has not yet been clearly demonstrated. This retrospective observational study aimed to verify their effectiveness by analyzing real-world data.</p><p><strong>Methods: </strong>Prescription and outpatient data from the National Database were extracted for October 2018, 2019, and 2020, covering both the Sakata area and the rest of Yamagata Prefecture. The number of prescriptions and cost per prescription were calculated for four therapeutic classes: proton pump inhibitors/potassium-competitive acid blockers, angiotensin receptor blockers, α-glucosidase inhibitors, and statins.</p><p><strong>Results: </strong>In 2020, the formulary adherence rate in Sakata exceeded that in the rest of Yamagata Prefecture across all therapeutic classes. Although the cost per prescription annually decreased in Sakata, some therapeutic classes showed increased costs in the remainder of the prefecture from 2019 to 2020. In contrast, formulary adherence to outpatient medical prescriptions was lower in Sakata, and no clear impact of the local formulary was observed. Applying the rate of cost reduction observed in Sakata to the rest of the prefecture, the estimated monthly savings reached approximately 35 million JPY after 1 year and 15 million JPY after 2 years. Furthermore, although no prior measures existed to control the use of originator drugs without generics, Sakata showed a trend of reduced usage compared with the rest of the prefecture, suggesting the influence of the local formulary.</p><p><strong>Conclusions: </strong>Local formularies can contribute to the sustainability of Japan's healthcare financing systems.</p>","PeriodicalId":16730,"journal":{"name":"Journal of Pharmaceutical Health Care and Sciences","volume":" ","pages":"114"},"PeriodicalIF":1.2,"publicationDate":"2025-12-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12751966/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145809805","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Evaluation of the pSMILE (Palliative care-Situational Motivating Interactive Learning and Education) educational program based on web-based and face-to-face workshops for palliative care pharmacists. 基于网络和面对面研讨会的姑息治疗药剂师pSMILE(姑息治疗-情境激励互动学习与教育)教育计划的评估。
IF 1.2 Q4 PHARMACOLOGY & PHARMACY Pub Date : 2025-12-20 DOI: 10.1186/s40780-025-00491-w
Megumi Kabeya, Mayako Uchida, Masahiko Amagawa, Makio Imamura, Yoko Kasahara, Yasunori Miyamoto, Takuya Yano, Takayuki Nakagawa

Background: In 2021, the Education and Training Committee of the Japanese Society for Pharmaceutical Palliative Care and Sciences established an educational training program for pharmacists in palliative care, named Palliative care-Situational Motivating Interactive Learning and Education (pSMILE), based on web-based and face-to-face workshops. The program aims to enhance pharmacists' knowledge of palliative care and develop communication and cooperation skills.

Methods: We constructed a web-based pSMILE training program, which was later adapted for face-to-face workshops. This program consisted of two sessions, with the first half at a hospital and the second half at a clinic or community pharmacy. The participants could choose from three learning scenarios. A post-survey (within 1 week of the workshop) assessed usefulness, difficulty, length, and satisfaction. Participants also completed a web-based survey on behavioral changes related to daily palliative care following the workshop. Nine items on behavioral changes were assessed before and 1 month after the workshop, which was held from April 2021 to March 2024.

Results: Twelve pSMILE workshops were held during this period (10 web-based and two face-to-face). A total of 296 pharmacists participated, 152 (51.4%) of whom were Board Certified Pharmacist in Palliative Pharmacy, and 292 (98.6%) responded to the before/after workshop survey. Usefulness ratings were 4.39 for Session I and 4.20 for Session II. Satisfaction ratings were high (≥ 4.5), with no significant differences based on affiliation, training format, or certification. All confidence scores of nine daily palliative care behaviors (symptom assessment; multidisciplinary information sharing; proposing pharmacotherapy; polypharmacy intervention; palliative pharmacotherapy with awareness of pharmacokinetics; explanation of delirium; response in the discharge conference; information sharing between hospitals, clinics, and community pharmacies; and pharmacotherapy suggestions in view of the post-discharge) improved significantly post-workshop (p < 0.01), across both web-based and face-to-face workshops. Certified participants had higher confidence scores both before and after the workshop, and each group showed a significant improvement.

Conclusions: These results suggest that either web-based or face-to-face pSMILE workshops improve the quality of pharmacists' contribution in daily palliative care. This is the first report on the effectiveness of an academically approved web-based educational program for palliative care pharmacists, comparable to face-to-face workshops.

背景:2021年,日本药物姑息治疗与科学学会教育培训委员会建立了一项针对姑息治疗药剂师的教育培训计划,名为姑息治疗-情境激励互动学习与教育(pSMILE),基于网络和面对面的研讨会。该项目旨在提高药剂师对姑息治疗的认识,并培养沟通和合作技能。方法:我们构建了一个基于网络的pSMILE培训计划,该计划后来被改编为面对面的研讨会。该项目分为两部分,前半部分在医院,后半部分在诊所或社区药房。参与者可以从三个学习场景中进行选择。会后调查(工作坊一周内)评估有用性、难度、时长和满意度。参与者还完成了一项基于网络的关于日常姑息治疗相关行为变化的调查。从2021年4月到2024年3月,在研修前和研修后1个月对9个项目进行了行为改变评估。结果:在此期间举办了12次pSMILE研讨会(10次网络研讨会和2次面对面研讨会)。共有296名药师参与,其中缓和药学注册药师152名(51.4%),参与工作坊前后调查的药师292名(98.6%)。会话1的有用性评分为4.39,会话2的有用性评分为4.20。满意度评分很高(≥4.5),没有基于隶属关系、培训形式或认证的显著差异。九项日常姑息治疗行为(症状评估、多学科信息共享、建议药物治疗、多种药物干预、了解药代动力学的姑息药物治疗、谵妄的解释、出院会议的反应、医院、诊所和社区药房之间的信息共享)的全信度评分;结论:这些结果表明,无论是基于网络的pSMILE研讨会还是面对面的pSMILE研讨会,都提高了药师在日常姑息治疗中的贡献质量。这是关于姑息治疗药剂师学术认可的基于网络的教育项目的有效性的第一份报告,可与面对面的研讨会相媲美。
{"title":"Evaluation of the pSMILE (Palliative care-Situational Motivating Interactive Learning and Education) educational program based on web-based and face-to-face workshops for palliative care pharmacists.","authors":"Megumi Kabeya, Mayako Uchida, Masahiko Amagawa, Makio Imamura, Yoko Kasahara, Yasunori Miyamoto, Takuya Yano, Takayuki Nakagawa","doi":"10.1186/s40780-025-00491-w","DOIUrl":"10.1186/s40780-025-00491-w","url":null,"abstract":"<p><strong>Background: </strong>In 2021, the Education and Training Committee of the Japanese Society for Pharmaceutical Palliative Care and Sciences established an educational training program for pharmacists in palliative care, named Palliative care-Situational Motivating Interactive Learning and Education (pSMILE), based on web-based and face-to-face workshops. The program aims to enhance pharmacists' knowledge of palliative care and develop communication and cooperation skills.</p><p><strong>Methods: </strong>We constructed a web-based pSMILE training program, which was later adapted for face-to-face workshops. This program consisted of two sessions, with the first half at a hospital and the second half at a clinic or community pharmacy. The participants could choose from three learning scenarios. A post-survey (within 1 week of the workshop) assessed usefulness, difficulty, length, and satisfaction. Participants also completed a web-based survey on behavioral changes related to daily palliative care following the workshop. Nine items on behavioral changes were assessed before and 1 month after the workshop, which was held from April 2021 to March 2024.</p><p><strong>Results: </strong>Twelve pSMILE workshops were held during this period (10 web-based and two face-to-face). A total of 296 pharmacists participated, 152 (51.4%) of whom were Board Certified Pharmacist in Palliative Pharmacy, and 292 (98.6%) responded to the before/after workshop survey. Usefulness ratings were 4.39 for Session I and 4.20 for Session II. Satisfaction ratings were high (≥ 4.5), with no significant differences based on affiliation, training format, or certification. All confidence scores of nine daily palliative care behaviors (symptom assessment; multidisciplinary information sharing; proposing pharmacotherapy; polypharmacy intervention; palliative pharmacotherapy with awareness of pharmacokinetics; explanation of delirium; response in the discharge conference; information sharing between hospitals, clinics, and community pharmacies; and pharmacotherapy suggestions in view of the post-discharge) improved significantly post-workshop (p < 0.01), across both web-based and face-to-face workshops. Certified participants had higher confidence scores both before and after the workshop, and each group showed a significant improvement.</p><p><strong>Conclusions: </strong>These results suggest that either web-based or face-to-face pSMILE workshops improve the quality of pharmacists' contribution in daily palliative care. This is the first report on the effectiveness of an academically approved web-based educational program for palliative care pharmacists, comparable to face-to-face workshops.</p>","PeriodicalId":16730,"journal":{"name":"Journal of Pharmaceutical Health Care and Sciences","volume":" ","pages":"109"},"PeriodicalIF":1.2,"publicationDate":"2025-12-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12720441/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145800548","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Preservation of eGFRcre for 1 year with HIF-PHI in non-dialysis patients: a retrospective observational cohort study. 非透析患者HIF-PHI中eGFRcre保存1年:一项回顾性观察队列研究。
IF 1.2 Q4 PHARMACOLOGY & PHARMACY Pub Date : 2025-12-20 DOI: 10.1186/s40780-025-00527-1
Tomohiro Aigami, Tomoyuki Ishigo, Mai Miyao, Masatoshi Nonoyama, Tomohisa Yamashita, Masayuki Koyama, Satoshi Fujii, Toshiyuki Yano, Masato Furuhashi, Masahide Fukudo, Takaki Toda
{"title":"Preservation of eGFRcre for 1 year with HIF-PHI in non-dialysis patients: a retrospective observational cohort study.","authors":"Tomohiro Aigami, Tomoyuki Ishigo, Mai Miyao, Masatoshi Nonoyama, Tomohisa Yamashita, Masayuki Koyama, Satoshi Fujii, Toshiyuki Yano, Masato Furuhashi, Masahide Fukudo, Takaki Toda","doi":"10.1186/s40780-025-00527-1","DOIUrl":"10.1186/s40780-025-00527-1","url":null,"abstract":"","PeriodicalId":16730,"journal":{"name":"Journal of Pharmaceutical Health Care and Sciences","volume":" ","pages":"10"},"PeriodicalIF":1.2,"publicationDate":"2025-12-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145800559","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Journal of Pharmaceutical Health Care and Sciences
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1